Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus ProteomicsTSE:4882 +4.20%57 3-Year ROIIC % is 300.93 as of Mar. 2026, which is 102% above its 10-year median of 149.02. GuruFocus rates TSE:4882 with a GF Score™ of 57/100 and a GF Value™ of 円440.33 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 948 Drug Manufacturers companies, Perseus Proteomics ranks better than 95.99% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Perseus Proteomics's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 300.93%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Perseus Proteomics's 3-Year ROIIC % or its related term are showing as below:
TSE:4882's 3-Year ROIIC % is ranked better than 95.99% of 948
companies
in the Drug Manufacturers industry
Industry Median: 3.675
vs TSE:4882: 300.93
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Perseus Proteomics 3-Year ROIIC % Related Terms
Perseus Proteomics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4882 vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Perseus Proteomics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's 3-Year ROIIC % falls into.
Perseus Proteomics's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -744.956 (Mar. 2026) - -697.77 (Mar. 2023) )
/
( 80.364 (Mar. 2026) - 96.044 (Mar. 2023) )
=
-47.186
/
-15.68
=
300.93%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Perseus Proteomics (TSE:4882) has a 3-Year ROIIC % of 300.93 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Perseus Proteomics and its competitors. This is 102% above median its historical median of 149.02. According to the industry distribution chart, Perseus Proteomics ranks #38 out of 948 companies in the Drug Manufacturers industry, placing it in the top 4%.
Is Perseus Proteomics' 3-Year ROIIC % too high?
Perseus Proteomics' current 3-Year ROIIC % of 300.93 is 102% above median its 10-year median of 149.02. The Drug Manufacturers industry median 3-Year ROIIC % is 3.68. Perseus Proteomics' value of 300.93 is 8088.6% above this industry median. Based on the distribution chart, Perseus Proteomics ranks #38 out of 948 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Perseus Proteomics has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #38 out of 948 companies for 3-Year ROIIC %. This places Perseus Proteomics in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.68. Perseus Proteomics' value of 300.93 is 8088.6% above this benchmark. While the company's 10-year median is 149.02 vs. the industry median of 3.68, Perseus Proteomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.68, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perseus Proteomics's current 3-Year ROIIC % of 300.93 is 8088.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Perseus Proteomics and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current 3-Year ROIIC % is 300.93, which is 102% above median its own 10-year median of 149.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円440.33, compared to a current price of 円149.00 — trading 66.2% below its estimated fair value. The current 3-Year ROIIC % is 300.93, which is 102% above median its 10-year median of 149.02 and 8088.6% above the Drug Manufacturers industry median of 3.68. Perseus Proteomics' overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current 3-Year ROIIC % is 300.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円149.00 is trading 66.2% below its estimated GF Value™ of 円440.33.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
3-Year ROIIC %: 300.93 (102% above median its 10-year median of 149.02)
GF Value™: 円440.33 vs. price of 円149.00 (66.2% below fair value)
Industry Position: 8088.6% above the Drug Manufacturers median (#38 of 948)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
57GF Score
Get the complete analysis for TSE:4882
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
